SCHEMBL572969

SCHEMBL572969

CCc1c(C)c(Cl)cc(C(C)C)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 4/20 0.48
GABRB1 P18505 3/20 0.48
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.42
TP53 P04637 2/20 0.42
CYP2C19 P33261 2/20 0.42
HIF1A Q16665 2/20 0.42
CYP2C9 P11712 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
HSP90AB1 P08238 1/20 0.40
GABRB2 P47870 2/20 0.39
GSR P00390 1/20 0.38
GAA P10253 4/20 0.37
HTT P42858 3/20 0.37
HPGD P15428 3/20 0.37
CASP7 P55210 3/20 0.37
HSD17B10 Q99714 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29810169 1.00 GABRA1 (0.48) GABRA1GABRB1LMNASMN1; SMN2TP53
Biclotymol SCHEMBL31496050 0.89 HIF1A (0.54) GABRA1GABRB1LMNASMN1; SMN2TP53
Biclotymol SCHEMBL70634 0.89 HIF1A (0.54) GABRA1GABRB1LMNASMN1; SMN2TP53
SCHEMBL19235936 0.83 CYP2C19 (0.49) GABRA1GABRB1LMNASMN1; SMN2TP53
SCHEMBL4235931 0.82 GABRA1 (0.42) GABRA1GABRB1LMNASMN1; SMN2TP53
SCHEMBL10988786 0.79 GAA (0.43) GABRA1GABRB1LMNASMN1; SMN2TP53
SCHEMBL27695866 0.78 FABP3 (0.46) LMNASMN1; SMN2TP53CYP2C19HIF1A
SCHEMBL6283809 0.76 GABRA1 (0.50) GABRA1GABRB1LMNAHIF1ACA1
SCHEMBL4613445 0.75 GABRA1 (0.54) GABRA1GABRB1LMNASMN1; SMN2TP53
SCHEMBL15698348 0.75 LMNA (0.52) GABRA1GABRB1LMNASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 749 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140135297-A1 AQUEOUS VOLATILE ORGANIC COMPOUND FREE DISINFECTANT AND/OR CLEANING COMPOSITION AND METHOD OF PREPARATION ISP INVESTMENTS INC. (US) 2014-05-15 US claimed
EP-2313026-A1 ACTIVE DELIVERY SYSTEM FORMULATIONS Castle Beach, L.L.C. (US) 2011-04-27 EP claimed
US-20100040565-A1 ACTIVE DELIVERY SYSTEMS FORMULATIONS Castle Beach, LLC (US) 2010-02-18 US claimed
WO-2010019680-A1 ACTIVE DELIVERY SYSTEM FORMULATIONS HOMOLA ANDREW M (US) 2010-02-18 WO claimed
US-20090214606-A1 ANTIMICROBIAL POROUS SILICON OXIDE PARTICLES CIBA SPECIALTY CHEMICALS CORP. 2009-08-27 US claimed
EP-1549731-B1 CLEANING AND DISINFECTING COMPOSITION RECKITT BENCKISER INC (US) 2008-12-17 EP claimed
EP-1879457-A1 ANTIMICROBIAL POROUS SILICON OXIDE PARTICLES Ciba Specialty Chemicals Holding, Inc. (CH) 2008-01-23 EP claimed
US-20070231295-A1 Antimicrobial Silicon Oxide Flakes CIBA SPECIALTY CHEMICALS CORP. 2007-10-04 US claimed
EP-1755381-A2 ANTIMICROBIAL SILICON OXIDE FLAKES CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement (CH) 2007-02-28 EP claimed
WO-2006120135-A1 ANTIMICROBIAL POROUS SILICON OXIDE PARTICLES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-11-16 WO claimed
US-20050233930-A1 Disinfectant cleaning compositions RECKITT BENCKISER INC. (US) 2005-10-20 US claimed
EP-1549730-A1 DISINFECTANT CLEANING COMPOSITIONS Reckitt Benckiser Inc. (US) 2005-07-06 EP claimed
EP-1549731-A1 CLEANING AND DISINFECTING COMPOSITION Reckitt Benckiser Inc. (US) 2005-07-06 EP claimed
EP-1537201-A1 HARD SURFACE TREATING COMPOSITIONS Reckitt Benckiser Inc. (US) 2005-06-08 EP claimed
EP-0805672-B1 METHODS, COMPOSITIONS, AND DENTAL DELIVERY SYSTEMS FOR THE PROTECTION OF THE SURFACES OF TEETH HOMOLA ANDREW M (US) 2004-08-25 EP claimed
WO-2004035724-A1 CLEANING AND DISINFECTING COMPOSITION RECKITT BENCKISER INC (US) 2004-04-29 WO claimed
WO-2004035723-A1 DISINFECTANT CLEANING COMPOSITIONS RECKITT BENCKISER INC (US) 2004-04-29 WO claimed
WO-2004024861-A1 HARD SURFACE TREATING COMPOSITIONS RECKITT BENCKISER INC (US) 2004-03-25 WO claimed
WO-2001093820-A1 ANTIPLAQUE AQUEOUS ORAL COMPOSITION RHODIA CHIMIE (FR) 2001-12-13 WO claimed
US-5665333-A Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth PROVSEAL LLC 1997-09-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100040565-A1 ACTIVE DELIVERY SYSTEMS FORMULATIONS LIPA, MMP7, CTSA GABRA1 3441/4885GABRB1 3285/4885LMNA 413/4885
US-20070231295-A1 Antimicrobial Silicon Oxide Flakes SIK2, SIK3, SIK1 GABRA1 4515/4885GABRB1 3994/4885LMNA 4300/4885
US-20090214606-A1 ANTIMICROBIAL POROUS SILICON OXIDE PARTICLES ORAI3, PRF1, THPO GABRA1 3123/4885GABRB1 2896/4885LMNA 4072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.